Navamedic ASA ("Navamedic") announced on 29 March 2023 a public takeover offer to the shareholders of Sensidose Aktiebolag. Sensidose has published the following information relating to the takeover offer: For further information, please see Navamedic's...
News en
Sensidose granted reimbursement for Flexilev in Finland
As part of Sensidose's ongoing geographical expansion, the company last autumn applied for reimbursement for Flexilev with the Finnish Pharmaceutical Price Board (Lääkkeiden hintalautakunta). The application has now been granted and the approval is in accordance with...
Sensidose’s founder talks about the company’s journey (Biostock interview)
The idea for Sensidose’s treatment strategy came about already in the mid-1990s when professors Sten-Magnus Aquilonius and Christer Nyström realized that it would be possible to personalise Parkinson’s treatment with microtablets. Today, the company’s drug Flexilev...
Sensidose recruits Deputy CEO for the expansion
Pharma company Sensidose has recruited Philip Slätis as Chief Operating Officer and Deputy CEO. Slätis takes on on his role on November 1 and brings broad experience from the pharmaceutical industry. He is expected to contribute to the company’s business development...
Sensidose reinforces its management. Philip Slätis has been hired as Chief Operating Officer and Deputy CEO of Sensidose AB. Philip will take up the position on 1st November in 2022
Sollentuna 1:a September 2022 Sensidose reinforces its management. Philip Slätis has been hired as Chief Operating Officer and Deputy CEO of Sensidose AB. Philip will take up the position on 1st November in 2022. - Philips' broad experience from all parts of the...
Biostock: Continued positive sales development for Sensidose
Sensidose recently reported an increase in net sales of 21 per cent for the second quarter compared to the same period in 2021. At the same time as the company is growing, they have also made progress during the quarter in the development of the new dosing device,...
Sensidose will participate at the BioStock Investor Meeting on March 16
Sensidose will participate at the BioStock Investor Meeting on March 16. The presentation starts at 14:05. Follow the event online here: https://youtu.be/tv-ZDUn3zzI https://youtu.be/tv-ZDUn3zzI #Sensidose #BioStockSWE #investormeeting #LifeSciences
Sensidose signs an agreement with Desitin Arzneimittel GmbH for sales and marketing of Flexilev/Suades in Germany
Sensidose AB (the "Company") has entered into a service agreement with Desitin Arzneimittel GmbH ("Desitin") for the sales and marketing of Flexilev (under the trade name Suades) in Germany. Sensidose and Desitin will share the revenue from the sales. The launch is...
Sensidose is awarded funding from Vinnova (Sweden´s Innovation Agency) to develop a method for objective registration and treatment of opiate-requiring pain conditions
Sensidose receives SEK 1.22 million in grants from Vinnova for industrial research within the call "Innovation projects in companies". The funding aims to support the company's development of measuring physiological reactions to pain to enable improved pain relief and...
Sensidose attended SALSS 2018 – All about Brains
Sensidose participated in the Swedish-American Life Science Summit (SALSS) between the 22nd to 24th of August 2018 in Stockholm, Sweden. The summit is a by-invitation-only conference bringing together some of the most renowned Life Science executives, scientists,...